Ordering Recommendation

Recommended test to confirm a diagnosis of a hereditary cancer syndrome in individuals with personal or family history consistent with features of more than one cancer syndrome. When a relative has a previously identified pathogenic sequence variant, see Familial Mutation, Targeted Sequencing (2001961).

Mnemonic
CANCERPAN
Methodology

Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Performed

Varies

Reported

3-6 weeks

New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA) or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions
Remarks
Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval

By report

Interpretive Data

Refer to report

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note

GENES TESTED: ALK, APC, ATM, ATR, AXIN2**, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2*, DICER1, EPCAM****, FH, FLCN, MAX, MEN1, MET, MLH1, MRE11, MSH2, MSH3**, MSH6, MUTYH, NBN, NF1**, NF2, NTHL1, PALB2, PHOX2B, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RB1, RECQL***, RET, SDHAF2, SDHB, SDHC*, SDHD*, SMAD4, SMARCA4**, SMARCB1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1**
 
* One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.
** Deletion/duplication detection is not available for this gene.
*** One or more exons are not covered by sequencing, and deletion/duplication detection is not available for this gene; see Additional Technical Information.
**** Deletion/duplication only; sequencing is not available for this gene.

Hotline History
N/A
CPT Codes

81432; 81433; 81435; 81436; 81437; 81438

Components
Component Test Code* Component Chart Name LOINC
2012033 Cancer Panel, Hereditary, Spcm 31208-2
2012034 Cancer Panel, Hereditary, Interp 35474-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Birt-Hogg-Dube (BHD) syndrome
  • Cowden syndrome
  • Familial Adenomatous Polyposis (FAP)
  • HBOC syndrome
  • Hereditary Diffuse Gastric Cancer (HDGC)
  • Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome
  • Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
  • Hereditary Papillary Renal Carcinoma (HPRC) syndrome
  • Hereditary Paraganglioma Pheochromocytoma
  • Juvenile Polyposis syndrome (JPS)
  • Li-Fraumeni syndrome (LFS)
  • Lynch syndrome
  • Malignant Mesothelioma
  • MUTYH-Associated Polyposis (MAP)
  • Peutz-Jegher syndrome (PJS)
  • PTEN Hamartoma Tumor syndrome
  • Rhabdoid Tumor Predisposition syndrome
  • Tuberous Sclerosis Complex (TSC)
  • Von Hippel Lindau (VHL) syndrome
  • Wilms Tumor
Hereditary Cancer Panel, Sequencing and Deletion/Duplication